Detalles de la búsqueda
1.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-29860938
2.
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 25(1): 73-85, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30153491
3.
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Biol Blood Marrow Transplant
; 24(8): 1581-1589, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29597002
4.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Blood
; 125(9): 1367-76, 2015 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25550361
5.
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.
J Immunol
; 194(4): 1434-45, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25595783
6.
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 16(9): 1025-1036, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26234174
7.
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Br J Haematol
; 168(6): 796-805, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403830
8.
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Blood
; 121(24): 4854-60, 2013 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23591789
9.
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Haematologica
; 100(2): 231-7, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25381131
10.
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.
Biol Blood Marrow Transplant
; 20(2): 222-8, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24211319
11.
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
Transfusion
; 54(12): 3131-7, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24947954
12.
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood
; 117(12): 3294-301, 2011 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21270442
13.
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Haematologica
; 103(11): e514-e518, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29794146
14.
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Transfusion
; 52(11): 2375-81, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22404694
15.
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.
Biol Blood Marrow Transplant
; 17(8): 1176-81, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21185389
16.
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Transfusion
; 51(9): 1995-2000, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21392017
17.
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet Haematol
; 8(7): e481-e491, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34171279
18.
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
Blood Adv
; 5(13): 2775-2787, 2021 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34251414
19.
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
JCO Oncol Pract
; 17(4): e497-e505, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125295
20.
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Br J Haematol
; 151(5): 430-4, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21113977